Published in Heart Fail Rev on December 01, 2007
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology (2009) 1.85
Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol (2007) 1.52
Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation (2012) 1.30
The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Trends Mol Med (2011) 1.24
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem (2010) 1.18
Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc Res (2009) 0.96
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.94
Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? Br J Pharmacol (2014) 0.93
Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat. Regul Pept (2008) 0.83
B-type natriuretic peptide levels predict extent and severity of coronary artery disease in non-ST elevation acute coronary syndrome and normal left ventricular function. Indian Heart J (2013) 0.82
Induction of cardioprotection by small netrin-1-derived peptides. Am J Physiol Cell Physiol (2015) 0.82
Corticotropin-releasing factor-2 activation prevents gentamicin-induced oxidative stress in cells derived from the inner ear. J Neurosci Res (2010) 0.80
Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol (2014) 0.80
Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties. J Biol Chem (2016) 0.80
Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers. J Am Heart Assoc (2016) 0.77
Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy. PLoS Biol (2017) 0.75
Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning. Arch Med Sci (2016) 0.75
Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. Front Pharmacol (2017) 0.75
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci (1981) 6.39
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation (1993) 4.85
Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun (1993) 4.32
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 4.24
Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev (2000) 4.10
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev (2005) 3.80
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 3.48
Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 3.37
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A (1995) 2.70
Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A (1993) 2.70
Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A (2000) 2.54
Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev (2000) 2.52
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev (2007) 2.14
N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis (2005) 1.96
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol (2003) 1.89
Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol (1949) 1.82
Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology (2003) 1.76
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol (2004) 1.70
Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab (2002) 1.66
Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol (2003) 1.63
Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol (2000) 1.61
Molecular biology of the natriuretic peptides and their receptors. Circulation (1992) 1.60
Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther (2004) 1.54
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther (2006) 1.44
Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res (2001) 1.43
Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation (1995) 1.41
Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation (1998) 1.36
C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol (2005) 1.31
Adrenomedullin--what do we know 10 years since its discovery? Pol J Pharmacol (2004) 1.30
Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem (2000) 1.29
Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun (1993) 1.28
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation (2004) 1.27
Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol (1992) 1.27
The natriuretic peptides. Basic Res Cardiol (2004) 1.26
Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol (2003) 1.23
C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides (2005) 1.22
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19
Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation (2003) 1.18
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension (2000) 1.16
Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun (1991) 1.12
Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation (1998) 1.12
Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart (2000) 1.07
Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol (2002) 1.06
Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation (2004) 1.04
Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension (2002) 1.01
Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J (1996) 1.01
Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol (2002) 1.00
Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol (1993) 0.99
Localization and physiological roles of urocortin. Peptides (2004) 0.98
Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol (2006) 0.98
Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest (1992) 0.98
Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology (1993) 0.97
Left ventricular size and shape: determinants of mechanical signal transduction pathways. Heart Fail Rev (2005) 0.95
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol (2000) 0.93
Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart (1998) 0.93
Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides (1998) 0.92
A-type and B-type natriuretic peptides in cardiac surgical procedures. Anesth Analg (2004) 0.92
CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol (1999) 0.91
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol (2001) 0.91
Plasma urocortin in human systolic heart failure. Clin Sci (Lond) (2004) 0.90
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol (2001) 0.90
K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation (2002) 0.90
Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA (2006) 0.89
Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. Trends Cardiovasc Med (2002) 0.89
Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. Am J Physiol Heart Circ Physiol (2000) 0.89
Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun (1999) 0.89
Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology (1994) 0.89
Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem Biophys Res Commun (1991) 0.88
Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation (2000) 0.88
Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J (2006) 0.88
Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation (2004) 0.87
C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun (1993) 0.87
Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation (1995) 0.86
Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction. Pharmacol Ther (2005) 0.86
Urocortins as cardiovascular peptides. Peptides (2004) 0.85
Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res (2000) 0.85
Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res (2004) 0.84
Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin. Drugs (1997) 0.84
Angiotensin and bradykinin peptides in rats with myocardial infarction. J Card Fail (1997) 0.84
Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun (1990) 0.84
Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res (2001) 0.84
Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart (1999) 0.83
Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem (2003) 0.83
The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med (2005) 0.83
AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol (1999) 0.83
Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. Br J Pharmacol (2003) 0.83
Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol Regul Integr Comp Physiol (2000) 0.83
Endothelium-independent relaxation by adrenomedullin in pregnant rat mesenteric artery: role of cAMP-dependent protein kinase A and calcium-activated potassium channels. J Pharmacol Exp Ther (2006) 0.83
Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta (2004) 0.82
Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacol Res (2006) 0.82
Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) (2005) 0.82
Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism. Am J Physiol Heart Circ Physiol (2001) 0.82
Kinins and cardioprotection. Pharmacol Res (1997) 0.82
Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J Pharmacol Exp Ther (1996) 0.82
Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol Cell Biochem (2003) 0.81
Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol (2005) 0.80
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev (2007) 3.19
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2010) 2.20
Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol (2007) 1.85
Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels. Basic Res Cardiol (2005) 1.73
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol (2003) 1.68
Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther (2004) 1.54
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19
Regulation of cardiovascular cell function by hydrogen sulfide (H(2)S). Cell Biochem Funct (2010) 1.07
Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept (2007) 1.06
B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol (2007) 1.06
Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium. Curr Pharm Des (2004) 0.94
Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol (2010) 0.93
Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol (2003) 0.91
Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther (2004) 0.88
Postconditioning signalling in the heart: mechanisms and translatability. Br J Pharmacol (2014) 0.88
L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther (2010) 0.87
NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc Res (2013) 0.86
Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction. Pharmacol Ther (2005) 0.86
Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol (2007) 0.85
Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacol Res (2006) 0.82
Nitrate tolerance does not increase production of peroxynitrite in the heart. Am J Physiol Heart Circ Physiol (2002) 0.81
Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol (2008) 0.80
Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol (2014) 0.80
Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium. Basic Res Cardiol (2009) 0.80
A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction. J Mol Cell Cardiol (2006) 0.79
Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation. J Cardiovasc Pharmacol Ther (2014) 0.79
Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropes. Cell Tissue Res (2013) 0.77
Effect of radiofrequency catheter ablation on the biochemical marker ischemia modified albumin. Am J Cardiol (2004) 0.75